Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BAY1161116 in Healthy Postmenopausal Women
NCT03119077Phase 1Terminated
- Sponsor
- Bayer
- Start
- Apr 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in polycystic ovary syndrome (PCOS) comparing BAY1161116 with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 5 weeks, Severity of Treatment-Emergent Adverse Events at 5 weeks and 2 more. Started Apr 2017; status: terminated.
02
Drugs
BAY 1161116
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT03119077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119077.